Trial Profile
A Randomized, Multicenter, Open-Label, Phase II Study Of VELCADE Alone Or VELCADE Plus Docetaxel In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2019
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Feb 2008 Status change from In progress to completed.
- 04 Sep 2005 New trial record.